← Leaderboards

Ivona Pandrea

Tulane University Of Louisiana

Google Scholar ↗PubMed ↗ORCID ↗

$33,088,190

Attributed

$38,485,712

Total exposure

52

Grants

47

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.1M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$38,485,712 · 52

By mechanism

R01$31,085,542 · 9

P01$4,349,304 · 2

P51$2,606,347 · 40

R21$444,519 · 1

Top collaborators

Most similar at Tulane University Of Louisiana

Same institution · by research overlap

Mahesh Mohan$12,801,428
Marlene S Orandle$1,359,068
Bapi Pahar$4,126,054
Namita Rout$7,643,352
Pete J Didier$2,580,809

Others in their field

Top investigators on “Infection”

Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
Judith S. Currier · University Of California Los Angeles$511,038,212
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497

Research focus

InfectionChronicNonhuman PrimateAcquired Immunodeficiency SyndromeCd4 Positive T LymphocytesPathogenesisMacacaCellsImmuneDisease ProgressionIntestinesTissuesReportingFundingVirusCercopithecus PygerythrusImmune ActivationInflammationDesignSourceAntiretroviral TherapyComorbidityBloodPlasma

Grant awards (97)

Impact of NETosis on SIV Pathogenesis and Response to Treatment$793,137

R01 · FY2025 · HL · contact PI

Impact of a Glucagon-Like Peptide-1 Receptor Agonist administration on SIV/HIV pathogenesis and ART$780,853

R01 · FY2025 · DK · contact PI

Probing the role of adenosine pathway in SIV pathogenesis$771,534

R01 · FY2025 · AI · contact PI

Assessing the Role of GI Tract Dysfunction to HIV/SIV Disease Progression$666,186

R01 · FY2025 · DK · contact PI

Probing the role of adenosine pathway in SIV pathogenesis$111,300

R01 · FY2025 · AI · contact PI

Impact of NETosis on SIV Pathogenesis and Response to Treatment$793,137

R01 · FY2024 · HL · contact PI

Probing the role of adenosine pathway in SIV pathogenesis$774,038

R01 · FY2024 · AI · contact PI

Assessing the Role of GI Tract Dysfunction to HIV/SIV Disease Progression$665,909

R01 · FY2024 · DK · contact PI

Probing the role of adenosine pathway in SIV pathogenesis$793,972

R01 · FY2023 · AI · contact PI

Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy$782,809

R01 · FY2023 · HL

Impact of NETosis on SIV Pathogenesis and Response to Treatment$781,337

R01 · FY2023 · HL · contact PI

Mechanistic Studies of Gut Dysfunction Exacerbation due to SARS-CoV-2 in HIV/SIV infected Individuals$397,500

R01 · FY2023 · DK · contact PI

Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy$782,809

R01 · FY2022 · HL

Impact of NETosis on SIV Pathogenesis and Response to Treatment$781,335

R01 · FY2022 · HL · contact PI

Mechanistic Studies of Gut Dysfunction Exacerbation due to SARS-CoV-2 in HIV/SIV infected Individuals$396,980

R01 · FY2022 · DK · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$779,322

R01 · FY2021 · HL · contact PI

Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy$774,257

R01 · FY2021 · HL

Assessing the Role of GI Tract Damage to HIV/SIV Disease Progression$707,610

R01 · FY2021 · DK · contact PI

Mechanistic Studies of Gut Dysfunction Exacerbation due to SARS-CoV-2 in HIV/SIV infected Individuals$391,250

R01 · FY2021 · DK · contact PI

Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy$799,089

R01 · FY2020 · HL

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$779,620

R01 · FY2020 · HL · contact PI

Assessing the Role of GI Tract Damage to HIV/SIV Disease Progression$734,500

R01 · FY2020 · DK · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$779,903

R01 · FY2019 · HL · contact PI

Assessing the Role of GI Tract Damage to HIV/SIV Disease Progression$732,881

R01 · FY2019 · DK · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$808,058

R01 · FY2018 · HL · contact PI

Assessing the Role of GI Tract Damage to HIV/SIV Disease Progression$715,521

R01 · FY2018 · DK · contact PI

Interventions to Reduce Hypercoagulability in Old SIV-Infected NHPs$708,651

R01 · FY2018 · HL · contact PI

Interventions to Reduce Hypercoagulability in Old SIV-Infected NHPs$769,909

R01 · FY2017 · HL · contact PI

Assessing the Role of GI Tract Damage to HIV/SIV Disease Progression$764,703

R01 · FY2017 · DK · contact PI

Interventions to Reduce Hypercoagulability in Old SIV-Infected NHPs$721,632

R01 · FY2017 · HL · contact PI

Interventions to Reduce Hypercoagulability in Old SIV-Infected NHPs$738,695

R01 · FY2016 · HL · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$645,283

R01 · FY2016 · HL · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$154,000

R01 · FY2016 · HL · contact PI

Interventions to Reduce Hypercoagulability in Old SIV-Infected NHPs$753,695

R01 · FY2015 · HL · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$721,435

R01 · FY2015 · HL · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$145,588

R01 · FY2015 · HL · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$725,728

R01 · FY2014 · HL · contact PI

Non-Human Primate Core$604,588

P01 · FY2014 · AI · contact PI

Non-Human Primate Core$1,206,858

P01 · FY2013 · AI · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$703,167

R01 · FY2013 · HL · contact PI

Non-Human Primate Core$927,631

P01 · FY2012 · AI · contact PI

SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques$756,042

R01 · FY2012 · HL · contact PI

Non-Human Primate Core$833,993

P01 · FY2011 · AI · contact PI

Non-Human Primate Core$776,234

P01 · FY2010 · AI · contact PI

Animal Model for SIV Infection Control$757,320

R01 · FY2010 · RR

Animal Model for SIV Infection Control$373,679

R01 · FY2010 · RR

Pathogenesis of SIV in African green monkeys$329,166

R01 · FY2010 · AI · contact PI

Animal Model for SIV Infection Control$756,918

R01 · FY2009 · RR

Pathogenesis of SIV in African green monkeys$689,089

R01 · FY2009 · AI · contact PI

Pathogenesis of SIV in African green monkeys$205,872

R01 · FY2009 · AI · contact PI

PAUCITY OF CD4+CCR5+ T CELLS AND BREASTFEEDING SIV TRANSMISSION$60,376

P51 · FY2009 · RR · contact PI

T REGULATORY CELLS IN AFRICAN GREEN MONKEYS AND RHESUS MACAQUES$60,376

P51 · FY2009 · RR · contact PI

SIVAGM INFECTION OF PIG-TAILED MACAQUES$60,376

P51 · FY2009 · RR · contact PI

PRIMARY SIV INFECTION DYNAMICS IN AFRICAN AND ASIAN MONKEYS$60,376

P51 · FY2009 · RR · contact PI

SIVAGM DYNAMICS IN AFRICAN GREEN MONKEYS$60,376

P51 · FY2009 · RR · contact PI

EXPERIMENTALLY-INDUCED IMMUNE ACTIVATION IN NATURAL HOSTS OF SIVS$60,376

P51 · FY2009 · RR · contact PI

T REGULATORY CELLS IN AFRICAN GREEN MONKEYS AND PIGTAILED MACAQUES$60,376

P51 · FY2009 · RR · contact PI

Pathogenesis of SIV in African green monkeys$383,693

R01 · FY2008 · AI · contact PI

EXPERIMENTALLY-INDUCED IMMUNE ACTIVATION IN NATURAL HOSTS OF SIVS$64,630

P51 · FY2008 · RR · contact PI

SIVAGM DYNAMICS IN AFRICAN GREEN MONKEYS$64,630

P51 · FY2008 · RR · contact PI

CD20 DEPLETION IN SIVAGM-INFECTED AGMS$64,630

P51 · FY2008 · RR · contact PI

PRIMARY SIV INFECTION DYNAMICS IN AFRICAN AND ASIAN MONKEYS$64,630

P51 · FY2008 · RR · contact PI

SIVAGM INFECTION OF PIG-TAILED MACAQUES$64,630

P51 · FY2008 · RR · contact PI

ROLE OF NK CELLS IN SIVAGM INFECTION$64,630

P51 · FY2008 · RR · contact PI

ACUTE LOSS OF CD4+ T CELLS IS NOT PREDICTIVE FOR SIV VIRULENCE$64,630

P51 · FY2008 · RR · contact PI

SEVERE CD4 T CELL DEPLETION IN SIVSM-INFECTED SOOTY MANGABEYS$64,630

P51 · FY2008 · RR · contact PI

T REGULATORY CELLS IN AFRICAN GREEN MONKEYS AND RHESUS MACAQUES$64,630

P51 · FY2008 · RR · contact PI

PAUCITY OF CD4+CCR5+ T CELLS IN NATURAL SIV HOSTS:A PROTECTIVE ROLE AGAINST AIDS$64,630

P51 · FY2008 · RR · contact PI

INNATE MUCOSAL IMMUNITY IN SIVMAC-INFECTED MACAQUES$63,253

P51 · FY2008 · RR · contact PI

Pathogenesis of SIV in African green monkeys$391,124

R01 · FY2007 · AI · contact PI

T regulatory cells in Rhesus Macaques and African green monkeys$200,269

R21 · FY2007 · AI · contact PI

ROLE OF NK CELLS IN SIVAGM INFECTION$71,639

P51 · FY2007 · RR · contact PI

DIFFERENT TGF-BETA PROFILES IN SIVMAC AND SIVAGM INFECTION$71,639

P51 · FY2007 · RR · contact PI

ACUTE LOSS OF CD4+ T CELLS IS NOT PREDICTIVE FOR SIV VIRULENCE$71,639

P51 · FY2007 · RR · contact PI

SEVERE CD4 T CELL DEPLETION IN SIVSM-INFECTED SOOTY MANGABEYS$71,639

P51 · FY2007 · RR · contact PI

SIVAGM INFECTION OF PIG-TAILED MACAQUES$71,639

P51 · FY2007 · RR · contact PI

SIV REPLICATION DYNAMICS IN AFRICAN NON-HUMAN PRIMATE HOSTS$71,639

P51 · FY2007 · RR · contact PI

SIVAGMVER REPLICATION IN VERVET AND SABAEUS AGM$71,639

P51 · FY2007 · RR · contact PI

SIMIAN IMMUNODEFICIENCY VIRUS SIVAGMSAB INFECTION OF CARIBBEAN AGMS$71,639

P51 · FY2007 · RR · contact PI

T REGULATORY CELLS IN AFRICAN GREEN MONKEYS AND RHESUS MACAQUES$71,639

P51 · FY2007 · RR · contact PI

PAUCITY OF CD4+CCR5+ T CELLS IN NATURAL SIV HOSTS:A PROTECTIVE ROLE AGAINST AIDS$71,638

P51 · FY2007 · RR · contact PI

Pathogenesis of SIV in African green monkeys$402,806

R01 · FY2006 · AI · contact PI

T regulatory cells in Rhesus Macaques and African green monkeys$244,250

R21 · FY2006 · AI · contact PI

SIV PATHOGENESIS IN THE NATURAL HOSTS$65,435

P51 · FY2006 · RR · contact PI

SIV REPLICATION DYNAMICS IN AFRICAN NON-HUMAN PRIMATE HOSTS$65,435

P51 · FY2006 · RR · contact PI

SIVAGMVER REPLICATION IN VERVET AND SABAEUS AGM$65,435

P51 · FY2006 · RR · contact PI

SIMIAN IMMUNODEFICIENCY VIRUS SIVAGMSAB INFECTION OF CARIBBEAN AGMS$65,435

P51 · FY2006 · RR · contact PI

T REGULATORY CELLS IN AFRICAN GREEN MONKEYS AND RHESUS MACAQUES$65,435

P51 · FY2006 · RR · contact PI

ANTI-INFLAMMATORY PROFILES DURING PRIMARY SIVAGM INFECTION$65,435

P51 · FY2006 · RR · contact PI

IMPACT OF VIRAL FACTORS ON REPLICATION PROFILES IN SIVAGM-INFECTED AGMS$65,435

P51 · FY2006 · RR · contact PI

PAUCITY OF CD4+CCR5+ T CELLS IN NATURAL SIV HOSTS:A PROTECTIVE ROLE AGAINST AIDS$65,435

P51 · FY2006 · RR · contact PI

IMMUNE RESPONSES INDUCED BY IMIQUIMOD: IMPLICATIONS FOR RHINOVIRUS INFECTIONS$30,971

P51 · FY2006 · RR · contact PI

Pathogenesis of SIV in African green monkeys$412,500

R01 · FY2005 · AI

ANTI-INFLAMMATORY PROFILES DURING PRIMARY SIVAGM INFECTION$54,500

P51 · FY2005 · RR

IMPACT OF VIRAL FACTORS ON REPLICATION PROFILES IN SIVAGM-INFECTED AGMS$54,500

P51 · FY2005 · RR

EARLY IN VIVO REPLICATION PROFILES OF SIVAGM$47,161

P51 · FY2004 · RR

LEVELS OF SIVMND-1 REPLICATION IN CHRONIC INFECTIONS$47,161

P51 · FY2004 · RR